Germany and Global Breast Cancer Therapeutics Market Size and Forecasts (2020 - 2030), Share, Trends, and Growth Opportunity Analysis - Report Coverage: By Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies)

Analyst Perspective:

Germany breast cancer therapeutics market accounted for US$ XX Mn in 2022, and it is expected to grow at a CAGR of 9.5% during the period 2022 - 2030, to reach US$ XX Mn in 2030. 

As per Globocan 2020, about 69,697 new instances of breast cancer were reported in 2020 in Germany, representing 11.1% of all registered cancer cases. It caused 20,579 fatalities, and the five-year prevalence rate of breast cancer in all ages was 707.38 per 100,000 population. Breast cancer treatment costs almost US$ 2.13 billion (2 billion euros) annually. According to the German Cancer Society, one in eight women will have breast cancer during their lifetime.

Numerous businesses run various programs to assist with breast cancer screenings, which can result in offering better treatment to the individual. For instance, in and around Paderborn, Germany, Radiologie am Theater has three special breast cancer diagnostic facilities. According to the center, more than 15,000 breast exams are performed annually in the country. In addition, women aged 50–69 can have a free mammogram every two years in the country. This helps detect breast cancer as early as possible to provide better treatment and increase the chances of recovery.

On the occasion of breast cancer awareness month in October, a unique campaign was initiated to shed light on the disease in October 2021. The campaign “Breast Cancer Affects Us All” has been created by Wefra Life, an advertising agency and a non-profit association Pink Ribbon Germany.

In June 2020, Vara, a Berlin-based company, aimed to save lives by making breast cancer screening accessible worldwide. It raised US$ 7.31 million (Euro 6.5 million) in a Series A funding round led by OMERS Ventures for AI-powered breast cancer screening software. Therefore, the growing disease burden is anticipated to promote the breast cancer therapeutics demand, along with its rising awareness in the country.

Market Segmentation - Breast Cancer Therapeutics Market

SEGMENT NAMETYPE

Drug TherapyTargeted Drug Therapy, Hormonal Drug Therapy, Chemotherapy, Immunotherapy/ Biological therapyTargeted Drug TherapyAbemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, Other Targeted Drug TherapyHormonal Drug TherapySelective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Selective Estrogen Receptor Downregulators (SERDs)Breast Cancer TypeHormone Receptor, HER2+ (human epidermal growth factor receptor 2), Triple-Negative Breast CancerDistribution ChannelHospital Pharmacies, Drug Store and Retail Pharmacies, Online Pharmacies

Key Player Analysis - Breast Cancer Therapeutics Market 

1. Eli Lilly and Co,
2. Eisai Co Ltd
3. Novartis AG
4. AstraZeneca Plc
5. Pfizer Inc
6. Gilead Sciences Inc
7. Merck & Co Inc
8. Genentech Inc
9. Teva Pharmaceutical Industries Ltd
10. Amgen Inc

are the key Breast Cancer Therapeutics Market players profiled in the report.

Germany and Global Breast Cancer Therapeutics Report Scope

The List of Companies - Breast Cancer Therapeutics Market 

1. Eli Lilly and Co,
2. Eisai Co Ltd
3. Novartis AG
4. AstraZeneca Plc
5. Pfizer Inc
6. Gilead Sciences Inc
7. Merck & Co Inc
8. Genentech Inc
9. Teva Pharmaceutical Industries Ltd
10. Amgen Inc